Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome
JAMA · 2025
DOI: 10.1001/jama.2025.13668 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA, 2025. Verfasst von Anne W T van der Wel und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Amsterdam University Medical Center location AMC, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Diabetes, Gestational, Dietary Supplements, Inositol, Polycystic Ovary Syndrome. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Pregnant individuals with polycystic ovary syndrome (PCOS) present with a higher risk of pregnancy complications, including gestational diabetes, preeclampsia, and preterm birth. Myo-inositol supplementation may reduce these risks.
Objective
To determine whether daily supplementation with myo-inositol during pregnancy among individuals with PCOS reduces the risk of a composite outcome of gestational diabetes, preeclampsia, and preterm birth. Design, Setting, and Participants This double-blind, placebo-controlled, randomized trial was conducted at 13 hospitals in the Netherlands. Pregnant individuals with PCOS who were between 8 and 16 weeks’ gestation were enrolled between June 2019 and March 2023. Final follow-up was complete on December 27, 2023. Analyses were conducted July 2024.
Interventions
Participants were randomized on a 1:1 basis to receive sachets with either myo-inositol, 2 g, with 0.2 mg of folic acid twice daily (n = 230) or matching placebo with 0.2 mg of folic acid only (n = 234) until delivery. Main Outcomes and Measures The primary outcome was a composite of gestational diabetes, preeclampsia, or preterm birth (before 37 weeks’ gestation).
Results
Among 464 participants, the mean (SD) age was 31.5 (3.8) years; 18 participants (3.9%) reported Asian race and 395 (86.1%) reported White race. The prevalence of biochemical hyperandrogenism was higher at baseline in the myo-inositol group than the placebo group (29.0% [53 of 180] vs 18.5% [37 of 193]). A primary outcome event occurred in 25.0% (n = 56) of participants in the myo-inositol group and 26.8% (n = 61) in the placebo group (relative risk, 0.93 [95% CI, 0.68-1.28]; P = .67). Conclusions and Relevance Myo-inositol supplementation during pregnancy did not reduce the incidence of a composite of gestational diabetes, preeclampsia, or preterm birth in patients with PCOS. Trial Registration onderzoekmetmensen.nl Identifier: NL67329.078.18
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Amsterdam University Medical Center location AMC, Amsterdam, the Netherlands.
- Amsterdam Reproduction & Development Research Institute, Amsterdam, the Netherlands.
- Department of Obstetrics and Gynecology, University Medical Center Utrecht, Utrecht, the Netherlands.
- Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Clinical Trials Unit of the Netherlands Society for Obstetrics and Gynaecology, Amsterdam, the Netherlands.
- Department of Obstetrics and Gynecology, Maastricht University Medical Centre, Maastricht, the Netherlands.
Zitieren
APA
van der Wel, A. W. T., Frank, C. M. C., Bout-Rebel, R., Duijnhoven, R. G., van Bree, B. E., Valkenburg, O., Al-Nasiry, S., van Oppenraaij, R. H. F., Vogelvang, T. E., Westerhuis, M. E. M. H., van de Nieuwenhof, H. P., Gielen, S. C. J. P., Bandell, M. L., Bekker, M. N., Wouters, M. G. A. J., Mijatovic, V., Franx, A., Lambalk, C. B., Broekmans, F. J. M., …, & van Rijn, B. B. (2025). Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome. JAMA. https://doi.org/10.1001/jama.2025.13668
Vancouver
van der Wel AWT, Frank CMC, Bout-Rebel R, Duijnhoven RG, van Bree BE, Valkenburg O, et al. Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome. JAMA. 2025. doi:10.1001/jama.2025.13668
BibTeX
@article{vanderWel2025,
author = {van der Wel, Anne W T and Frank, Chryselle M C and Bout-Rebel, Rebekka and Duijnhoven, Ruben G and van Bree, Bo E and Valkenburg, Olivier and Al-Nasiry, Salwan and van Oppenraaij, Robbert H F and Vogelvang, Tatjana E and Westerhuis, Michelle E M H and van de Nieuwenhof, Hedwig P and Gielen, Susanne C J P and Bandell, Myrthe L and Bekker, Mireille N and Wouters, Maurice G A J and Mijatovic, Velja and Franx, Arie and Lambalk, Cornelis B and Broekmans, Frank J M and de Weerd, Sabina and Gerards, Jet M H and Baalman, Jelle H and van Disseldorp, Jeroen and Langenveld, Josje and Gunning, Marlise N and Frederix, Geert W J and Painter, Rebecca C and Fauser, Bart C J M and Laven, Joop S E and van Rijn, Bas B},
title = {Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome},
journal = {JAMA},
year = {2025},
doi = {10.1001/jama.2025.13668}
}
EUVIMED